HCPLive Network

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Further Reading
Do longer periods of androgen-deprivation therapy significantly improve prostate cancer survival rates or needlessly impair quality of life for recovering patients?
There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors compared to sulfonylureas and thiazolidinediones for glycemic control, according to a study published online Sept. 10 in Diabetes, Obesity and Metabolism.
Watchful waiting may not be suitable for all men with early-stage prostate cancer, especially black patients, according to research published in Urologic Oncology.
Breast feeding can potentially protect premature babies from a toxic gastrointestinal disease, according to a recent study published in in the American Journal of Pathology.
Although it is widely understood that hepatitis B virus (HBV) and hepatitis C virus (HCV) are the leading causes of liver cirrhosis and liver cancer, an alarming number of HBV and HCV carriers have unhealthy habits that result in poor liver health.
According to researchers at the Stanford University School of Medicine, an ultraviolet light-induced genetic mutation is the probable culprit fueling countless human skin cancers.
Soy protein may increase activity in genes linked to breast cancer growth -- at least in certain women who already have the disease, according to research reported in the September issue of the Journal of the National Cancer Institute.
More Reading